Experts Discuss TURALIO
View a multidisciplinary discussion and product overview of TURALIO.


Mechanism of action of pexidartinib1
alt MOA

Pexidartinib has been shown to affect CSR-1R on both neoplastic and healthy cells.

CSF-1, colony-stimulating factor 1; CSF-1R, colony-stimulating factor 1 receptor.



factor 1

CSF-1 overexpression is a driver
of TGCT2,3

  • Overexpression of the colony-stimulating factor 1 receptor (CSF-1R) ligand promotes cell proliferation and accumulation in the synovium1
  • Binding of the CSF-1 ligand to the CSF-1R leads to activation of signaling pathways that modulate differentiation, proliferation, and chemotaxis toward the source of CSF-1, leading to the recruitment of inflammatory cells to the joint cavity2


factor 1 receptor

TURALIO targets a pathway that often leads to TGCT1

TURALIO, an oral small-molecule tyrosine kinase inhibitor (TKI)1:

  • INHIBITS CSF-1R, impeding autocrine and paracrine stimulation1,4–9
  • INACTIVATES CSF-1R, stabilizing it in an inactive form10
  • IMPEDES the recruitment of some inflammatory cells4–7
  • TURALIO also inhibits tyrosine kinase activity of c-KIT and mutant FMS-like tyrosine kinase 3 (FLT3).1

Prescribing TURALIO1 Because of the risk of hepatotoxicity, TURALIO is available only through a Risk Evaluation and Mitigation Strategy (REMS) program. Under TURALIO REMS, only certified healthcare providers and pharmacies may prescribe and dispense TURALIO. In addition, a registry is used to collect information about the effects of taking TURALIO over time. Patients must complete and sign an enrollment form for the TURALIO REMS Program and the registry.

Further information is available at turalioREMS.com or by telephone at 1-833-887-2546.
Further information is available at turalioREMS.com or by telephone at